Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at the German Center for Neurodegenerative Diseases (DZNE) and Charité—Universitätsmedizin Berlin have now discovered how the cortisone compound influences the impaired inflammatory response and which patients benefit from it. Their method uses single-cell analyses and raises hopes for a precise prediction tool for other therapies and diseases as well. The findings have been published in the journal Cell. It has long been puzzling why certain drugs work Read More